| Year |
Citation |
Score |
| 2012 |
Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 485: 55-61. PMID 22367541 DOI: 10.1038/Nature10912 |
0.526 |
|
| 2012 |
Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Investigational New Drugs. 30: 2219-25. PMID 22270257 DOI: 10.1007/S10637-012-9793-Y |
0.704 |
|
| 2010 |
Chuluunbaatar U, Roller R, Feldman ME, Brown S, Shokat KM, Mohr I. Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication. Genes & Development. 24: 2627-39. PMID 21123650 DOI: 10.1101/Gad.1978310 |
0.552 |
|
| 2010 |
Feldman ME, Shokat KM. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). Current Topics in Microbiology and Immunology. 347: 241-62. PMID 20549474 DOI: 10.1007/82_2010_64 |
0.62 |
|
| 2010 |
Lu M, Wang J, Jones KT, Ives HE, Feldman ME, Yao LJ, Shokat KM, Ashrafi K, Pearce D. mTOR complex-2 activates ENaC by phosphorylating SGK1. Journal of the American Society of Nephrology : Jasn. 21: 811-8. PMID 20338997 DOI: 10.1681/Asn.2009111168 |
0.562 |
|
| 2010 |
Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM, Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 17: 249-61. PMID 20227039 DOI: 10.1016/J.Ccr.2010.01.021 |
0.552 |
|
| 2009 |
Herbert SP, Huisken J, Kim TN, Feldman ME, Houseman BT, Wang RA, Shokat KM, Stainier DY. Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science (New York, N.Y.). 326: 294-8. PMID 19815777 DOI: 10.1126/Science.1178577 |
0.645 |
|
| 2009 |
Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Plos Biology. 7: e38. PMID 19209957 DOI: 10.1371/Journal.Pbio.1000038 |
0.714 |
|
| 2009 |
Sly LM, Hamilton MJ, Kuroda E, Ho VW, Antignano FL, Omeis SL, van Netten-Thomas CJ, Wong D, Brugger HK, Williams O, Feldman ME, Houseman BT, Fiedler D, Shokat KM, Krystal G. SHIP prevents lipopolysaccharide from triggering an antiviral response in mice. Blood. 113: 2945-54. PMID 19139077 DOI: 10.1182/Blood-2008-06-166082 |
0.664 |
|
| 2008 |
Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chemical Biology. 4: 691-9. PMID 18849971 DOI: 10.1038/Nchembio.117 |
0.73 |
|
| 2007 |
Knight ZA, Feldman ME, Balla A, Balla T, Shokat KM. A membrane capture assay for lipid kinase activity. Nature Protocols. 2: 2459-66. PMID 17947987 DOI: 10.1038/Nprot.2007.361 |
0.668 |
|
| 2006 |
Simon MD, Feldman ME, Rauh D, Maris AE, Wemmer DE, Shokat KM. Structure and properties of a re-engineered homeodomain protein-DNA interface. Acs Chemical Biology. 1: 755-60. PMID 17240973 DOI: 10.1021/Cb6003756 |
0.666 |
|
| 2006 |
Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 125: 733-47. PMID 16647110 DOI: 10.1016/J.Cell.2006.03.035 |
0.679 |
|
| 2006 |
Magarvey NA, Beck ZQ, Simon MD, Feldman ME, Rosivatz E, Pokharel S. Introduction to Our Authors Acs Chemical Biology. 1: 728-729. DOI: 10.1021/Cb600482X |
0.504 |
|
| Show low-probability matches. |